Browse PLCG2

Summary
SymbolPLCG2
Namephospholipase C, gamma 2 (phosphatidylinositol-specific)
Aliases APLAID; FCAS3; PLC-IV; PLC-gamma-2; phosphoinositide phospholipase C-gamma-2; phospholipase C-IV; Phospholip ......
Chromosomal Location16q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF00168 C2 domain
PF00388 Phosphatidylinositol-specific phospholipase C
PF00387 Phosphatidylinositol-specific phospholipase C
PF00017 SH2 domain
PF00018 SH3 domain
Function

The production of the second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) is mediated by activated phosphatidylinositol-specific phospholipase C enzymes. It is a crucial enzyme in transmembrane signaling.

> Gene Ontology
 
Biological Process GO:0001819 positive regulation of cytokine production
GO:0002090 regulation of receptor internalization
GO:0002092 positive regulation of receptor internalization
GO:0002218 activation of innate immune response
GO:0002220 innate immune response activating cell surface receptor signaling pathway
GO:0002223 stimulatory C-type lectin receptor signaling pathway
GO:0002237 response to molecule of bacterial origin
GO:0002263 cell activation involved in immune response
GO:0002285 lymphocyte activation involved in immune response
GO:0002312 B cell activation involved in immune response
GO:0002313 mature B cell differentiation involved in immune response
GO:0002316 follicular B cell differentiation
GO:0002335 mature B cell differentiation
GO:0002366 leukocyte activation involved in immune response
GO:0002429 immune response-activating cell surface receptor signaling pathway
GO:0002431 Fc receptor mediated stimulatory signaling pathway
GO:0002433 immune response-regulating cell surface receptor signaling pathway involved in phagocytosis
GO:0002521 leukocyte differentiation
GO:0002757 immune response-activating signal transduction
GO:0002758 innate immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0006066 alcohol metabolic process
GO:0006644 phospholipid metabolic process
GO:0006650 glycerophospholipid metabolic process
GO:0006661 phosphatidylinositol biosynthetic process
GO:0006816 calcium ion transport
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0006898 receptor-mediated endocytosis
GO:0006909 phagocytosis
GO:0007204 positive regulation of cytosolic calcium ion concentration
GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0008654 phospholipid biosynthetic process
GO:0009395 phospholipid catabolic process
GO:0010959 regulation of metal ion transport
GO:0016042 lipid catabolic process
GO:0016055 Wnt signaling pathway
GO:0019722 calcium-mediated signaling
GO:0019751 polyol metabolic process
GO:0019932 second-messenger-mediated signaling
GO:0022898 regulation of transmembrane transporter activity
GO:0030098 lymphocyte differentiation
GO:0030100 regulation of endocytosis
GO:0030168 platelet activation
GO:0030183 B cell differentiation
GO:0031349 positive regulation of defense response
GO:0031623 receptor internalization
GO:0032237 activation of store-operated calcium channel activity
GO:0032409 regulation of transporter activity
GO:0032411 positive regulation of transporter activity
GO:0032412 regulation of ion transmembrane transporter activity
GO:0032414 positive regulation of ion transmembrane transporter activity
GO:0032479 regulation of type I interferon production
GO:0032481 positive regulation of type I interferon production
GO:0032496 response to lipopolysaccharide
GO:0032606 type I interferon production
GO:0032844 regulation of homeostatic process
GO:0032845 negative regulation of homeostatic process
GO:0032957 inositol trisphosphate metabolic process
GO:0032958 inositol phosphate biosynthetic process
GO:0032959 inositol trisphosphate biosynthetic process
GO:0034762 regulation of transmembrane transport
GO:0034764 positive regulation of transmembrane transport
GO:0034765 regulation of ion transmembrane transport
GO:0034767 positive regulation of ion transmembrane transport
GO:0038093 Fc receptor signaling pathway
GO:0038094 Fc-gamma receptor signaling pathway
GO:0038095 Fc-epsilon receptor signaling pathway
GO:0038096 Fc-gamma receptor signaling pathway involved in phagocytosis
GO:0042113 B cell activation
GO:0043112 receptor metabolic process
GO:0043270 positive regulation of ion transport
GO:0043647 inositol phosphate metabolic process
GO:0044242 cellular lipid catabolic process
GO:0044283 small molecule biosynthetic process
GO:0045017 glycerolipid biosynthetic process
GO:0045088 regulation of innate immune response
GO:0045089 positive regulation of innate immune response
GO:0045807 positive regulation of endocytosis
GO:0046165 alcohol biosynthetic process
GO:0046173 polyol biosynthetic process
GO:0046434 organophosphate catabolic process
GO:0046474 glycerophospholipid biosynthetic process
GO:0046486 glycerolipid metabolic process
GO:0046488 phosphatidylinositol metabolic process
GO:0048259 regulation of receptor-mediated endocytosis
GO:0048260 positive regulation of receptor-mediated endocytosis
GO:0050817 coagulation
GO:0050851 antigen receptor-mediated signaling pathway
GO:0050852 T cell receptor signaling pathway
GO:0050853 B cell receptor signaling pathway
GO:0050878 regulation of body fluid levels
GO:0051208 sequestering of calcium ion
GO:0051209 release of sequestered calcium ion into cytosol
GO:0051235 maintenance of location
GO:0051238 sequestering of metal ion
GO:0051282 regulation of sequestering of calcium ion
GO:0051283 negative regulation of sequestering of calcium ion
GO:0051480 regulation of cytosolic calcium ion concentration
GO:0051924 regulation of calcium ion transport
GO:0051928 positive regulation of calcium ion transport
GO:0055074 calcium ion homeostasis
GO:0060401 cytosolic calcium ion transport
GO:0060402 calcium ion transport into cytosol
GO:0060627 regulation of vesicle-mediated transport
GO:0070509 calcium ion import
GO:0070588 calcium ion transmembrane transport
GO:0070838 divalent metal ion transport
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
GO:0072511 divalent inorganic cation transport
GO:0097553 calcium ion transmembrane import into cytosol
GO:0198738 cell-cell signaling by wnt
GO:1901019 regulation of calcium ion transmembrane transporter activity
GO:1901021 positive regulation of calcium ion transmembrane transporter activity
GO:1901339 regulation of store-operated calcium channel activity
GO:1901341 positive regulation of store-operated calcium channel activity
GO:1901615 organic hydroxy compound metabolic process
GO:1901617 organic hydroxy compound biosynthetic process
GO:1902656 calcium ion import into cytosol
GO:1903169 regulation of calcium ion transmembrane transport
GO:1904062 regulation of cation transmembrane transport
GO:1904064 positive regulation of cation transmembrane transport
GO:1904427 positive regulation of calcium ion transmembrane transport
GO:2000021 regulation of ion homeostasis
GO:2001257 regulation of cation channel activity
GO:2001259 positive regulation of cation channel activity
Molecular Function GO:0004435 phosphatidylinositol phospholipase C activity
GO:0004620 phospholipase activity
GO:0004629 phospholipase C activity
GO:0008081 phosphoric diester hydrolase activity
GO:0016298 lipase activity
GO:0042578 phosphoric ester hydrolase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04012 ErbB signaling pathway
hsa04014 Ras signaling pathway
hsa04020 Calcium signaling pathway
hsa04064 NF-kappa B signaling pathway
hsa04066 HIF-1 signaling pathway
hsa04070 Phosphatidylinositol signaling system
hsa04360 Axon guidance
hsa04370 VEGF signaling pathway
hsa04380 Osteoclast differentiation
hsa04611 Platelet activation
hsa04650 Natural killer cell mediated cytotoxicity
hsa04662 B cell receptor signaling pathway
hsa04664 Fc epsilon RI signaling pathway
hsa04666 Fc gamma R-mediated phagocytosis
hsa04670 Leukocyte transendothelial migration
hsa04722 Neurotrophin signaling pathway
hsa04750 Inflammatory mediator regulation of TRP channels
hsa04919 Thyroid hormone signaling pathway
hsa00562 Inositol phosphate metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-983695: Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
R-HSA-5621481: C-type lectin receptors (CLRs)
R-HSA-5607764: CLEC7A (Dectin-1) signaling
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-5621480: Dectin-2 family
R-HSA-2871809: FCERI mediated Ca+2 mobilization
R-HSA-2871796: FCERI mediated MAPK activation
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-2029480: Fcgamma receptor (FCGR) dependent phagocytosis
R-HSA-114604: GPVI-mediated activation cascade
R-HSA-109582: Hemostasis
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-1483249: Inositol phosphate metabolism
R-HSA-1430728: Metabolism
R-HSA-139943: PLC-mediated hydrolysis of PIP2
R-HSA-76002: Platelet activation, signaling and aggregation
R-HSA-2029485: Role of phospholipids in phagocytosis
R-HSA-983705: Signaling by the B Cell Receptor (BCR)
R-HSA-1855204: Synthesis of IP3 and IP4 in the cytosol
R-HSA-166016: Toll Like Receptor 4 (TLR4) Cascade
R-HSA-168898: Toll-Like Receptors Cascades
Summary
SymbolPLCG2
Namephospholipase C, gamma 2 (phosphatidylinositol-specific)
Aliases APLAID; FCAS3; PLC-IV; PLC-gamma-2; phosphoinositide phospholipase C-gamma-2; phospholipase C-IV; Phospholip ......
Chromosomal Location16q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PLCG2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between PLCG2 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
24127488Melanoma; Lung Carcinoma; Pancreatic CarcinomaPromote immunityWe demonstrate that down-regulation of PLCĪ³2 signaling in MDSCs is responsible for their aberrant expansion during tumor progression. PLCĪ³2(-/-) MDSCs show stronger immune-suppressive activity against CD8(+) T cells than WT MDSCs and potently promote tumor growth when adoptively transferred into WT mice.
Summary
SymbolPLCG2
Namephospholipase C, gamma 2 (phosphatidylinositol-specific)
Aliases APLAID; FCAS3; PLC-IV; PLC-gamma-2; phosphoinositide phospholipase C-gamma-2; phospholipase C-IV; Phospholip ......
Chromosomal Location16q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PLCG2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPLCG2
Namephospholipase C, gamma 2 (phosphatidylinositol-specific)
Aliases APLAID; FCAS3; PLC-IV; PLC-gamma-2; phosphoinositide phospholipase C-gamma-2; phospholipase C-IV; Phospholip ......
Chromosomal Location16q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PLCG2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0320.937
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.6590.428
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.4280.535
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1380.732
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.420.828
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.8450.739
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.5740.194
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.950.446
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1670.904
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.8220.462
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.4470.38
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1120.35
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PLCG2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.42.74.70.294
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.43.440.587
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916018.8-18.80.28
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59022.2-22.20.505
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.33.71.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPLCG2
Namephospholipase C, gamma 2 (phosphatidylinositol-specific)
Aliases APLAID; FCAS3; PLC-IV; PLC-gamma-2; phosphoinositide phospholipase C-gamma-2; phospholipase C-IV; Phospholip ......
Chromosomal Location16q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PLCG2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPLCG2
Namephospholipase C, gamma 2 (phosphatidylinositol-specific)
Aliases APLAID; FCAS3; PLC-IV; PLC-gamma-2; phosphoinositide phospholipase C-gamma-2; phospholipase C-IV; Phospholip ......
Chromosomal Location16q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PLCG2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PLCG2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPLCG2
Namephospholipase C, gamma 2 (phosphatidylinositol-specific)
Aliases APLAID; FCAS3; PLC-IV; PLC-gamma-2; phosphoinositide phospholipase C-gamma-2; phospholipase C-IV; Phospholip ......
Chromosomal Location16q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PLCG2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPLCG2
Namephospholipase C, gamma 2 (phosphatidylinositol-specific)
Aliases APLAID; FCAS3; PLC-IV; PLC-gamma-2; phosphoinositide phospholipase C-gamma-2; phospholipase C-IV; Phospholip ......
Chromosomal Location16q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PLCG2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPLCG2
Namephospholipase C, gamma 2 (phosphatidylinositol-specific)
Aliases APLAID; FCAS3; PLC-IV; PLC-gamma-2; phosphoinositide phospholipase C-gamma-2; phospholipase C-IV; Phospholip ......
Chromosomal Location16q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PLCG2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPLCG2
Namephospholipase C, gamma 2 (phosphatidylinositol-specific)
Aliases APLAID; FCAS3; PLC-IV; PLC-gamma-2; phosphoinositide phospholipase C-gamma-2; phospholipase C-IV; Phospholip ......
Chromosomal Location16q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PLCG2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.